Jay Shubrook
Family Medicine · Vallejo, CANPI 1336179704
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (53.6%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Novo Nordisk at 26.6% of the total. Among family medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 277 payments — averaging $616.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$45K
- Boehringer Ingelheim$32K
- Sanofi-aventis U.S. LLC$32K
- Abbott$13K
- Corcept Therapeutics$11K
- Novo Nordisk AS$9K
- plus $28K from 19 others
Across 106 payments — averaging $3584.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$188K
- Abbott$125K
- Bayer$52K
- Sanofi-aventis U.S. LLC$10K
- Dexcom, Inc.$2K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- plus $2K from 2 others
What the payments were for
- Consulting fees$91,50054%
- Speaking & faculty fees$59,25835%
- Grants$5000%
- Travel & lodging$13,2328%
- Food & beverage$6,1034%
- Education$40%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 72 | $45,409 |
| Boehringer Ingelheim | 30 | $32,214 |
| Sanofi-aventis U.S. LLC | 24 | $32,184 |
| Abbott | 28 | $12,851 |
| Corcept Therapeutics | 16 | $10,882 |
| Novo Nordisk AS | 4 | $8,670 |
| Eli Lilly | 5 | $7,220 |
| Bayer | 31 | $6,157 |
| Insulet Corporation | 5 | $4,595 |
| Idorsia Pharmaceuticals US Inc | 2 | $3,818 |
| AstraZeneca | 7 | $3,596 |
| Nevro Corp. | 3 | $1,000 |
| Madrigal Pharmaceuticals | 2 | $630 |
| Sanofi | 1 | $500 |
| Lilly USA, LLC | 20 | $275 |
| Viiv Healthcare Company | 6 | $123 |
| Mannkind Corporation | 4 | $117 |
| Medtronic(2 entities) | 4 | $109 |
| Johnson & Johnson(2 entities) | 3 | $98 |
| Merck | 5 | $90 |
| Lifescan, Inc. | 1 | $49 |
| BD | 1 | $20 |
| Zealand Pharma US, Inc. | 1 | $18 |
| Hologic Sales And Service, LLC | 1 | $18 |
| EMD Serono, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SOLIQUA 100/33$27,349
- JARDIANCE$19,150
- Korlym$10,458
- Victoza$7,725
- Omnipod$4,582
- Afinion 2$3,975
- Tryvio$3,818
- Kerendia$3,801
- FARXIGA$3,491
- RYBELSUS$3,283
- Non-Covered$1,800
- ALERE AFINION HBA1C CONTROL$1,225
- Omnia$1,000
- AFINION HBA1C DX$875
- REZDIFFRA$630
- ALERE AFINION ACR CONTROL$414
- TZIELD$170
- FREESTYLE LIBRE 3$121
How this compares
$170,657 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 59 | $70,318 |
| OzempicSemaglutide | 37 | $37,783 |
| TrulicityDulaglutide | 23 | $35,379 |
| MounjaroTirzepatide | 31 | $32,932 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 21 | $13,569 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 37 | $12,648 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 15 | $1,294 |
| Ultra-Fine Mini Pen NeedlePen Needle, Diabetic | 13 | $740 |
| Metformin Hcl | 26 | $148 |
| Lisinopril | 23 | $107 |
| Atorvastatin Calcium | 17 | $80 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $32,214 | $70,31859 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $275 | $68,31154 claims |
| Novo NordiskOzempic | $45,409 | $37,78337 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.
Other family medicine in Vallejo
- Sherly SoleimanEncino$1.2M
- Pamela KushnerLos Angeles$1.2M
- Sujata NarayanStanford$1.2M
- Jeffrey UngerChino$906K
- Alexander RivkinLos Angeles$866K
- Scott HowellLos Angeles$793K
- Derrick ButlerLos Angeles$692K
- Sandra CalmanMontara$589K
- Anthony JonesOakland$377K
- Amira AyadBakersfield$360K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.